

ATTY. DOCKET NO.	SERIAL NO.
4821-362	09/447,218
APPLICANT	A. Aberg et al. (Divisional of Appln. No. 09/039,260)
FILING DATE	GROUP
Concurrently Herewith	Art. Unit 1623

FPO  
5/23/99

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
**	AA	5,595,997	1/97	Aberg et al.	514	290	
	AB	5,089,496	2/92	Piwinski et al.	514	253	
	AC	5,019,591	5/91	Gardner et al.	514	461	
	AD	4,777,170	10/88	Heinrich	514	226.2	
	AE	4,659,716	4/87	Villani et al.	514	290	
	AF	4,282,233	8/81	Villani	424	267	
	AG	3,940,485	2/76	Levinson et al.	424	250	
	AH	3,598,123	8/71	Zaffaroni	128	268	
	AI	3,536,809	10/70	Applezweig	424	28	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AJ	WO 92/11034	7/92	PCT	- - -	- - -	
	AK	WO 92/00293	1/92	PCT	- - -	- - -	
	AL	0 288 640	11/88	EPA	- - -	- - -	
	AM	WO 85/03707	8/85	PCT	- - -	- - -	
	AN	WO 96/20708	7/96	PCT	- - -	- - -	
	AO	WO 92/20377	11/92	PCT	- - -	- - -	

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

AP !	Babe et al., 1996, "Histamine, Bradykinin, and Their Antagonists", Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 581-593 and 598-599
AQ !	McCue, J., 1996, "Safety of Antihistamines in the Treatment of Allergic Rhinitis in Elderly Patients", Arch. Fam. Med. 5:464-468
AR !	Andersen et al., 1995, "Adverse Drug Interactions Clinically Important for the Dermatologist", Arch. Dermatol. 131:468-473
AS !	Peggs et al., 1995, "Antihistamines: The Old and The New", American Family Physician 52(2):593-600
AT !	Berthon et al., 1994, "In Vitro Inhibition, by Loratadine and Descarboxyethoxloratadine, of Histamine Release from Human Basophils, and of Histamine Release and Intracellular Calcium Fluxes in Rat Basophilic Leukemia Cells (RBL-2H3)", Biochemical Pharmacology 47(5): 789-794
AU !	Brandes et al., 1994, "Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H <sub>1</sub> -Antihistamines: Predictive In Vitro Correlates", J. Nat. Can. Inst. Reports 86(10): 770-775

\*\* Duplicate of reference already of record on PTO-892.

<i>Jee</i>	AV!	Kleine-Tebbe et al., 1994, "Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H <sub>1</sub> -antagonist, desethoxycarbonyl-loratadine", J. Allergy Clin. Immunol. 93(2):494-500
<i>Jee</i>	AW!	Miadonna et al., 1994, "Inhibitory Effect of the H <sub>1</sub> Antagonist Loratadine on Histamine Release from Human Basophils", Int. Arch. Allergy Immunol. 105:12-17
<i>Jee</i>	AX!	Simons, F.E.R., 1994, "H <sub>1</sub> -Receptor Antagonists Comparative Tolerability and Safety", Drug Safety 10(5):350-380
<i>Jee</i>	AY!	Zhong et al., 1994, "HPLC-Bestimmung Von Loratadin und seinem aktiven Metaboliten Descarboethoxyloratadin in Humanplasma", Pharmazie 49(10):736-739 (English abstract attached)
<i>Jee</i>	AZ!	Quercia et al., 1993, "Focus on loratadine: A new second-generation nonsedating H <sub>1</sub> -receptor antagonist", Hosp. Formul. 28:137-149, 153
<i>Jee</i>	BA!	Lavrijsen et al., 1993, "The Interaction of Ketoconazole, Itraconazole and Erythromycin With the In Vitro Metabolism of Antihistamines in Human Liver Microsomes", Abstract 1233 Eur. J. Allergy Clin. Immunol. 48(Suppl. 16):34
<i>Jee</i>	BB!	Roman et al., 1993, "Loratadine A Review of Recent Findings in Pharmacology, Pharmacokinetics, Efficacy, and Safety, with a Look at Its Use in Combination with Pseudoephedrine", Clinical Reviews in Allergy 11:89-110
<i>Jee</i>	BC!	Van Peer et al., 1993, "Ketoconazole Inhibits Loratadine Metabolism in Man", Abstract 1234 Eur. J. Allergy Clin. Immunol. 48(Suppl. 16):34
<i>Jee</i>	BD!	Product Insert CR-318/17597400 7/93 Schering Corporation (1992, 1993)
<i>Jee</i>	BE!	Brandes et al., 1992, "Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses", Cancer Research 52:3796-3800
<i>Jee</i>	BF!	Kaliner, M., 1992, "Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects", American Family Physician 45(3):1337-1342
<i>Jee</i>	BG!	Knowles, 1992, "Astemizole and Terfenadine - Induced Cardiovascular Effects", Canadian J. Hosp. Pharm. 45(1):33, 37
<i>Jee</i>	BH!	Parkinson et al., 1992, "Evaluation of Loratadine as an Inducer of Liver Microsomal Cytochrome P450 In Rats and Mice", Biochemical Pharmacology 43(10):2169-2180
<i>Jee</i>	BI!	Van Cauwenberge, P., 1992, "New Data on the Safety of Loratadine", Drug Invest. 4(4):283-291
<i>Jee</i>	BJ!	Barnett et al., 1991, "Pharmacology of Non-Sedating H <sub>1</sub> Antihistamines", New Perspectives in Histamine Research pp. 181-196
<i>Jee</i>	BK!	"Antihistamines", 1990, Chapter 16 Side Effects of Drugs Annual 14:135-138 Elsevier Science Publishers
<i>Jee</i>	BL!	Gengo, F.M, 1990, "Delimma: Antihistamine Selection: Use vs. Side Effects", U.S. Pharmacist pp. 59-72, 92
<i>Jee</i>	BM!	Clissold et al., 1989, "Loratadine A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy", Drugs 37:42-57
<i>Jee</i>	BN!	"Antihistamines", 1988, Chapter 16 Side Effects of Drugs Annual 12:142-143 Elsevier Science Publishers
<i>Jee</i>	BO!	Simons et al., 1988, "Astemizole - Induced Torsades de Pointes", Lancet p. 624

! Month of publication data is unavailable for this reference.

<i>Re</i>	BP !	Temple et al., 1988, "Loratadine, an Antihistamine, Blocks antigen- and Ionophore - Induced Leukotriene Release From Human Lung In Vitro", Prostaglandins 35(4):549-554
<i>Re</i>	BQ !	Hilbert et al., 1987, " Pharmacokinetics and Dose Proportionality of Loratadine", J. Clin. Pharmacol. 27:694-698
<i>Re</i>	BR !	Craft, 1986, "Torsade de Pointes After Astemizole Overdose", British Med. J. 292:660
<i>Re</i>	BS !	Barnett et al., 1984, " Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine", Agents and Actions 14(5/6):590-597
<i>Re</i>	BT !	Wood, 1979, "Antimotion Sickness and Antiemetic Drugs", Drugs 17(17):471-479
<i>Re</i>	BU !	Cohen et al., 1972, "Meclizine and Placebo in Treating Vertigo of Vestibular Origin", Arch. Neurol. 27:129-135
<i>Re</i>	BV !	Goodman and Gilman's, 1996, The Pharmacological Basis of Therapeutics, 9th Ed. p. 148, 588-592
<i>Re</i>	BW !	Carmeliet, 1992, "Voltage- and Time-Dependent Block of the Delayed K <sup>+</sup> Current in Cardiac Myocytes by Dofetilide", J. Pharmacol. Exper. Ther. 262:809-817
<i>Re</i>	BX !	Lunde, I., 1990, "Antihistamines", Side Effects of Drugs 14:135-138
<i>Re</i>	BY !	Dukes, M.N.G. et al., 1988, "Side Effects of Drugs Annual 12", Elsevier Science Publishers B.V. pp. 142-143
<i>Re</i>	BZ !	Ebert, W., 1977, "Soft Elastic Gelatin Capsules: A Unique Dosage Form", Pharmaceutical Technology 1:44-50
<i>Re</i>	CA !	Petrin, A., 1974, "Motion Sickness and its Treatment", Schweiz. Med. 63:79-81
<i>Re</i>	CB !	Wood, C.D. et al., 1987, "Mechanisms of Antimotion Sickness Drugs", Aviation, Space, and Envir. Med. pp. A262-A265
EXAMINER	L. E. Crane <i>L. Crane</i>	DATE CONSIDERED 03/21/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

! Month of publication data is unavailable for this reference.